PARP-1 selectively impairs KRAS -driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.

Autor: Keggenhoff FL; First Department of Internal Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Castven D; Department of Medicine I, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany., Becker D; First Department of Internal Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Stojkovic S; Department of Medicine I, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany., Castven J; Department of Medicine I, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany., Zimpel C; Department of Medicine I, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany., Straub BK; Institute of Pathology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.; Tissue Biobank of the University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Gerber T; Institute of Pathology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Langer H; Cardiology Angiology, University Medical Centre, Mannheim, Germany., Hähnel P; Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Kindler T; Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Fahrer J; Department of Chemistry, RPTU Kaiserslautern-Landau, Kaiserslautern, Germany., O'Rourke CJ; Department of Health and Medical Sciences, University of Copenhagen Biotech Research & Innovation Centre, Kobenhavn, Denmark., Ehmer U; Department of Internal Medicine II, Klinikum rechts der Isar der Technischen Universitat, München, Germany., Saborowski A; Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany., Ma L; Laboratory of Human Carcinogenesis, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland, USA., Wang XW; Laboratory of Human Carcinogenesis, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland, USA.; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Gaiser T; Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany., Matter MS; Institute of Pathology, University Hospital Basel, Basel, Switzerland., Sina C; Institute of Nutritional Medicine, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany., Derer S; Institute of Nutritional Medicine, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany., Lee JS; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Roessler S; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Kaina B; Department of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Andersen JB; Department of Health and Medical Sciences, University of Copenhagen Biotech Research & Innovation Centre, Kobenhavn, Denmark., Galle PR; First Department of Internal Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Marquardt JU; Department of Medicine I, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany Jens.Marquardt@uksh.de.

Publikováno v: Gut [Gut] 2024 Sep 09; Vol. 73 (10), pp. 1712-1724. Date of Electronic Publication: 2024 Sep 09.